HSF1 and ovarian carcinoma: This compound displayed a good PK profile across differentspecies and excellent therapeutic efficacy, including tumor regression,from a low free exposure in an in vivo human ovarian cancer xenograftmouse model, and demonstrated biomarker modulation in tumor tissueconsistent with the HSF1 pathway inhibition—representing overalla strong pharmacological audit trail.41